Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2020 · 10-Q
Revenue$0.00$0.00no prior Q3 2019 on file Net Income-$1.91M-$1.91MN/M vs Q3 2019 EPS Diluted-$0.02-$0.02N/M vs Q3 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flowderived-$817,482N/M ended Sep 30, 2020 · filed Nov 20, 2020 · 51 d after period end